Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes

Kouichirou Tahara, Kazutoh Takesako, Alessandro Sette, Esteban Celis, Seigo Kitano, Tsuyoshi Akiyoshi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Because MAGE-2 gene is expressed in a wide variety of malignant tumors and HLA-A24 is the most common allele in the Japanese population and is also frequently present in Caucasians, the identification of MAGE-2-encoded peptide presented by HLA-A24 is, therefore, considered to be important in order to develop specific immunotherapy for malignant tumors using peptides as a vaccine. By using a MHC-binding assay, eight peptides derived from MAGE- 2 were found to bind with sufficient affinity to the HLA-A24 molecule. When the induction of specific cytotoxic T lymphocytes (CTLs) was examined using a simplified method, the highest human lymphocyte antigen (HLA) binder (EYLQLVFGI) in these peptides was able to elicit CTLs from unseparated peripheral blood mononuclear cells in HLA-A24 healthy donors by stimulation with freshly isolated, peptide-pulsed peripheral blood mononuclear cells as antigen-presenting cells and also by using interleukin 7 and keyhole-limpet hemocyanin in a primary culture. The induced CTL could, thus, lyse HLA-A24 tumor cells expressing MAGE-2, as well as the peptide-pulsed target cells, with antigen specificity in a HLA class I-restricted manner. The identification of this peptide may, thus, be of therapeutic value in peptide- based vaccines for the treatment of several types of malignant tumors expressing MAGE-2.

Original languageEnglish (US)
Pages (from-to)2236-2241
Number of pages6
JournalClinical Cancer Research
Volume5
Issue number8
StatePublished - Aug 1 1999

Fingerprint

Cytotoxic T-Lymphocytes
HLA Antigens
Lymphocytes
Peptides
Antigens
Blood Cells
Interleukin-7
Neoplasms
Histocompatibility Antigens Class I
Subunit Vaccines
Neoplasm Antigens
Antigen-Presenting Cells
Immunotherapy
Vaccines
Alleles
Therapeutics
Population
Genes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. / Tahara, Kouichirou; Takesako, Kazutoh; Sette, Alessandro; Celis, Esteban; Kitano, Seigo; Akiyoshi, Tsuyoshi.

In: Clinical Cancer Research, Vol. 5, No. 8, 01.08.1999, p. 2236-2241.

Research output: Contribution to journalArticle

Tahara, Kouichirou ; Takesako, Kazutoh ; Sette, Alessandro ; Celis, Esteban ; Kitano, Seigo ; Akiyoshi, Tsuyoshi. / Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 8. pp. 2236-2241.
@article{a59814bbacd94b6ebe9be866ce513048,
title = "Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes",
abstract = "Because MAGE-2 gene is expressed in a wide variety of malignant tumors and HLA-A24 is the most common allele in the Japanese population and is also frequently present in Caucasians, the identification of MAGE-2-encoded peptide presented by HLA-A24 is, therefore, considered to be important in order to develop specific immunotherapy for malignant tumors using peptides as a vaccine. By using a MHC-binding assay, eight peptides derived from MAGE- 2 were found to bind with sufficient affinity to the HLA-A24 molecule. When the induction of specific cytotoxic T lymphocytes (CTLs) was examined using a simplified method, the highest human lymphocyte antigen (HLA) binder (EYLQLVFGI) in these peptides was able to elicit CTLs from unseparated peripheral blood mononuclear cells in HLA-A24 healthy donors by stimulation with freshly isolated, peptide-pulsed peripheral blood mononuclear cells as antigen-presenting cells and also by using interleukin 7 and keyhole-limpet hemocyanin in a primary culture. The induced CTL could, thus, lyse HLA-A24 tumor cells expressing MAGE-2, as well as the peptide-pulsed target cells, with antigen specificity in a HLA class I-restricted manner. The identification of this peptide may, thus, be of therapeutic value in peptide- based vaccines for the treatment of several types of malignant tumors expressing MAGE-2.",
author = "Kouichirou Tahara and Kazutoh Takesako and Alessandro Sette and Esteban Celis and Seigo Kitano and Tsuyoshi Akiyoshi",
year = "1999",
month = "8",
day = "1",
language = "English (US)",
volume = "5",
pages = "2236--2241",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes

AU - Tahara, Kouichirou

AU - Takesako, Kazutoh

AU - Sette, Alessandro

AU - Celis, Esteban

AU - Kitano, Seigo

AU - Akiyoshi, Tsuyoshi

PY - 1999/8/1

Y1 - 1999/8/1

N2 - Because MAGE-2 gene is expressed in a wide variety of malignant tumors and HLA-A24 is the most common allele in the Japanese population and is also frequently present in Caucasians, the identification of MAGE-2-encoded peptide presented by HLA-A24 is, therefore, considered to be important in order to develop specific immunotherapy for malignant tumors using peptides as a vaccine. By using a MHC-binding assay, eight peptides derived from MAGE- 2 were found to bind with sufficient affinity to the HLA-A24 molecule. When the induction of specific cytotoxic T lymphocytes (CTLs) was examined using a simplified method, the highest human lymphocyte antigen (HLA) binder (EYLQLVFGI) in these peptides was able to elicit CTLs from unseparated peripheral blood mononuclear cells in HLA-A24 healthy donors by stimulation with freshly isolated, peptide-pulsed peripheral blood mononuclear cells as antigen-presenting cells and also by using interleukin 7 and keyhole-limpet hemocyanin in a primary culture. The induced CTL could, thus, lyse HLA-A24 tumor cells expressing MAGE-2, as well as the peptide-pulsed target cells, with antigen specificity in a HLA class I-restricted manner. The identification of this peptide may, thus, be of therapeutic value in peptide- based vaccines for the treatment of several types of malignant tumors expressing MAGE-2.

AB - Because MAGE-2 gene is expressed in a wide variety of malignant tumors and HLA-A24 is the most common allele in the Japanese population and is also frequently present in Caucasians, the identification of MAGE-2-encoded peptide presented by HLA-A24 is, therefore, considered to be important in order to develop specific immunotherapy for malignant tumors using peptides as a vaccine. By using a MHC-binding assay, eight peptides derived from MAGE- 2 were found to bind with sufficient affinity to the HLA-A24 molecule. When the induction of specific cytotoxic T lymphocytes (CTLs) was examined using a simplified method, the highest human lymphocyte antigen (HLA) binder (EYLQLVFGI) in these peptides was able to elicit CTLs from unseparated peripheral blood mononuclear cells in HLA-A24 healthy donors by stimulation with freshly isolated, peptide-pulsed peripheral blood mononuclear cells as antigen-presenting cells and also by using interleukin 7 and keyhole-limpet hemocyanin in a primary culture. The induced CTL could, thus, lyse HLA-A24 tumor cells expressing MAGE-2, as well as the peptide-pulsed target cells, with antigen specificity in a HLA class I-restricted manner. The identification of this peptide may, thus, be of therapeutic value in peptide- based vaccines for the treatment of several types of malignant tumors expressing MAGE-2.

UR - http://www.scopus.com/inward/record.url?scp=0032792104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032792104&partnerID=8YFLogxK

M3 - Article

C2 - 10473111

AN - SCOPUS:0032792104

VL - 5

SP - 2236

EP - 2241

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -